Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Head and Neck Cancer

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 58 articles:
HTML format

Single Articles

    November 2022
  1. ROBBINS HA, Ferreiro-Iglesias A, Waterboer T, Brenner N, et al
    Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium.
    J Clin Oncol. 2022;40:3613-3622.
    PubMed     Abstract available

    October 2022
  2. PATIL VM, Noronha V, Menon N, Rai R, et al
    Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.
    J Clin Oncol. 2022 Oct 20:JCO2201015. doi: 10.1200/JCO.22.01015.
    PubMed     Abstract available

  3. HO AL
    Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    J Clin Oncol. 2022 Oct 12:JCO2201408. doi: 10.1200/JCO.22.01408.
    PubMed     Abstract available

  4. HARRINGTON KJ, Burtness B, Greil R, Soulieres D, et al
    Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
    J Clin Oncol. 2022 Oct 11:JCO2102508. doi: 10.1200/JCO.21.02508.
    PubMed     Abstract available

    August 2022
  5. MCLEOD DSA, Bedno SA, Cooper DS, Hutfless SM, et al
    Pre-existing Thyroid Autoimmunity and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study of US Active-Duty Personnel.
    J Clin Oncol. 2022;40:2578-2587.
    PubMed     Abstract available

  6. MARON SB, Moya S, Morano F, Emmett MJ, et al
    Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.
    J Clin Oncol. 2022;40:2458-2467.
    PubMed     Abstract available

    July 2022
  7. PATEL MA, Kratz JD, Lubner SJ, Loconte NK, et al
    Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice.
    J Clin Oncol. 2022 Jul 15:JCO2102500. doi: 10.1200/JCO.21.02500.
    PubMed     Abstract available

  8. PRICE JM, Mistry HB, Betts G, Cheadle EJ, et al
    Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer.
    J Clin Oncol. 2022;40:2203-2212.
    PubMed     Abstract available

    June 2022
  9. ZHANG Y, Chen L, Hu GQ, Zhang N, et al
    Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.
    J Clin Oncol. 2022 Jun 16:JCO2200327. doi: 10.1200/JCO.22.00327.
    PubMed     Abstract available

  10. NORONHA V, Patil VM, Menon N, Prabhash K, et al
    Change in Pattern of Failure in Head and Neck Cancer.
    J Clin Oncol. 2022 Jun 16:JCO2200598. doi: 10.1200/JCO.22.00598.

  11. BROSE MS, Pryma DA, Newbold KL
    Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study.
    J Clin Oncol. 2022;40:1847-1849.

  12. HO AL, Dedecjus M, Wirth LJ, Tuttle RM, et al
    Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).
    J Clin Oncol. 2022;40:1870-1878.
    PubMed     Abstract available

    May 2022
  13. GUPTA T, Maheshwari G, Kannan S, Nair S, et al
    Should Sentinel Lymph Node Biopsy Be Considered the New Standard of Care for Early-Stage Clinically Node-Negative Oral Squamous Cell Carcinoma?
    J Clin Oncol. 2022;40:1706-1709.

  14. MCDONALD AM, Lindeman B, Bahl D
    Radioactive Iodine: Recognizing the Need for Risk-Benefit Balance.
    J Clin Oncol. 2022;40:1396-1399.

  15. PASQUAL E, Schonfeld S, Morton LM, Villoing D, et al
    Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
    J Clin Oncol. 2022;40:1439-1449.
    PubMed     Abstract available

    April 2022
  16. HAYES DN, Gleysteen JP, Schwartz DL
    For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting.
    J Clin Oncol. 2022 Apr 21:JCO2200274. doi: 10.1200/JCO.22.00274.

  17. SHEN L, Kato K, Kim SB, Ajani JA, et al
    Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
    J Clin Oncol. 2022 Apr 20:JCO2101926. doi: 10.1200/JCO.21.01926.
    PubMed     Abstract available

  18. FRANCO AT, Ricarte-Filho JC, Isaza A, Jones Z, et al
    Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers.
    J Clin Oncol. 2022;40:1081-1090.
    PubMed     Abstract available

  19. FERRIS RL, Burtness B, Flamand Y
    Reply to A.S. Garden.
    J Clin Oncol. 2022;40:1133-1134.

  20. FAGIN JA
    Age of Onset of Receptor Tyrosine Kinase Fusions Drives Distinct Biologic Outcomes in Thyroid Cancer.
    J Clin Oncol. 2022;40:1124-1126.

    March 2022
  21. BURTNESS B, Rischin D, Greil R, Soulieres D, et al
    Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
    J Clin Oncol. 2022 Mar 25:JCO2102198. doi: 10.1200/JCO.21.02198.
    PubMed     Abstract available

  22. MOWERY YM, Salama JK
    Interpreting ORATOR: Lessons Learned From a Randomized Comparison of Primary Surgical and Radiation Approaches for Early-Stage Oropharyngeal Cancer.
    J Clin Oncol. 2022;40:814-817.

  23. NICHOLS AC, Theurer J, Prisman E, Read N, et al
    Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial.
    J Clin Oncol. 2022;40:866-875.
    PubMed     Abstract available

  24. KIYOTA N, Tahara M, Mizusawa J, Kodaira T, et al
    Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.
    J Clin Oncol. 2022 Mar 1:JCO2101293. doi: 10.1200/JCO.21.01293.
    PubMed     Abstract available

    February 2022
  25. NG WT, Chua MLK, Lee AWM
    Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: Quo Vadis?
    J Clin Oncol. 2022 Feb 25:JCO2200099. doi: 10.1200/JCO.22.00099.

    Transoral Surgery With Neck Dissection Is an Excellent Treatment for the Appropriately Selected Patient With Early-Stage Oropharyngeal Cancer.
    J Clin Oncol. 2022 Feb 16:JCO2102630. doi: 10.1200/JCO.21.02630.

  27. ZHAO JJ, Yap DWT, Chan YH, Tan BKJ, et al
    Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    J Clin Oncol. 2022;40:392-402.
    PubMed     Abstract available

    January 2022
  28. CHAUKAR D, Prabash K, Rane P, Patil VM, et al
    Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer.
    J Clin Oncol. 2022;40:272-281.
    PubMed     Abstract available

  29. MCDOWELL L, Magarey MJR, Rischin D
    Transoral Surgery and Deintensified Adjuvant Therapy: Another Step in Determining Its Role in the Management of Human Papillomavirus Oropharyngeal Cancer.
    J Clin Oncol. 2022;40:114-117.

  30. FERRIS RL, Flamand Y, Weinstein GS, Li S, et al
    Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
    J Clin Oncol. 2022;40:138-149.
    PubMed     Abstract available

  31. LI XY, Luo DH, Guo L, Mo HY, et al
    Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial.
    J Clin Oncol. 2022 Jan 6:JCO2101467. doi: 10.1200/JCO.21.01467.
    PubMed     Abstract available

    December 2021
  32. HO AL
    Androgen Receptor Pathway in Salivary Gland Cancer.
    J Clin Oncol. 2021;39:4069-4072.

  33. LOCATI LD, Cavalieri S, Bergamini C, Resteghini C, et al
    Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial.
    J Clin Oncol. 2021;39:4061-4068.
    PubMed     Abstract available

  34. KEILTY D, Khandwala M, Liu ZA, Papaioannou V, et al
    Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children.
    J Clin Oncol. 2021;39:3813-3821.
    PubMed     Abstract available

    November 2021
  35. XU B, Fuchs TL, Ahmadi S, Alghamdi M, et al
    International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.
    J Clin Oncol. 2021 Nov 3:JCO2101329. doi: 10.1200/JCO.21.01329.
    PubMed     Abstract available

  36. ADENIS A, Kulkarni AS, Girotto GC, de la Fouchardiere C, et al
    Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
    J Clin Oncol. 2021 Nov 3:JCO2100601. doi: 10.1200/JCO.21.00601.
    PubMed     Abstract available

    October 2021
  37. SHAH MA, Hofstetter WL, Kennedy EB
    Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update.
    J Clin Oncol. 2021;39:3182-3184.
    PubMed     Abstract available

    September 2021
  38. POTTGEN C, Nestle U, Hocht S, Stuschke M, et al
    Interactions Between Dose and Volume in Chemoradiotherapy of Esophageal Cancer.
    J Clin Oncol. 2021 Sep 23:JCO2101579. doi: 10.1200/JCO.21.01579.

    August 2021
  39. KALRA B, Sinha S, Laskar SG
    De-Escalation in HPV: Near Yet Elusive.
    J Clin Oncol. 2021;39:2733-2734.

  40. CMELAK AJ, Ferris RL, Chen AM, Seiwert T, et al
    Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?
    J Clin Oncol. 2021;39:2732-2733.

  41. HONG S, Zhang Y, Yu G, Peng P, et al
    Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.
    J Clin Oncol. 2021 Aug 11:JCO2100396. doi: 10.1200/JCO.21.00396.
    PubMed     Abstract available

  42. LI B, Chen H
    The Best Surgery Should Be Applied for Locally Advanced Esophageal Cancer.
    J Clin Oncol. 2021 Aug 2:JCO2101340. doi: 10.1200/JCO.21.01340.

    June 2021
  43. HULSHOF MCCM, Geijsen ED, Rozema T, Oppedijk V, et al
    Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study).
    J Clin Oncol. 2021 Jun 8:JCO2003697. doi: 10.1200/JCO.20.03697.
    PubMed     Abstract available

  44. GOODMAN KA, Ou FS, Hall NC, Bekaii-Saab T, et al
    Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
    J Clin Oncol. 2021 Jun 2:JCO2003611. doi: 10.1200/JCO.20.03611.
    PubMed     Abstract available

    May 2021
  45. HIRSHOREN N, Weinberger JM
    Surgical Perspective on Sentinel Node Biopsy for Operable T1-T2N0 Oral and Oropharyngeal Cancer.
    J Clin Oncol. 2021;39:1598-1599.

  46. LIU MA, Hsu WT, Johnstone C, Chang A, et al
    Interpreting the Clinical Utility of Early Interdisciplinary Supportive Care for Untreated Metastatic Esophageal Cancer.
    J Clin Oncol. 2021 May 7:JCO2100122. doi: 10.1200/JCO.21.00122.

  47. YOKOYAMA K, Ishiki H
    Questions Regarding Patient-Reported Symptom Burden as a Predictor of Emergency Department Use and Unplanned Hospitalization in Head and Neck Cancer.
    J Clin Oncol. 2021 May 5:JCO2100456. doi: 10.1200/JCO.21.00456.

    April 2021
  48. EYCK BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, et al
    Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
    J Clin Oncol. 2021 Apr 23:JCO2003614. doi: 10.1200/JCO.20.03614.
    PubMed     Abstract available

  49. PEARSON AT, Vokes EE
    Is This the Dawn of Precision Oncology in Head and Neck Cancer?
    J Clin Oncol. 2021 Apr 20:JCO2100569. doi: 10.1200/JCO.21.00569.

  50. HASEGAWA Y, Tsukahara K, Yoshimoto S, Miura K, et al
    Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial.
    J Clin Oncol. 2021 Apr 20:JCO2003637. doi: 10.1200/JCO.20.03637.
    PubMed     Abstract available

  51. MINAMI H, Kiyota N, Omori T
    Did the Randomized Phase III KEYNOTE-181 Study of Pembrolizumab for Esophageal Cancer Yield Negative or Positive Results?
    J Clin Oncol. 2021 Apr 12:JCO2003262. doi: 10.1200/JCO.20.03262.

    March 2021
  52. CHUNDURY A, Kim S
    Radiation Dose De-Escalation in HPV-Positive Oropharynx Cancer: When Will It Be an Acceptable Standard of Care?
    J Clin Oncol. 2021;39:947-949.

  53. YOM SS, Torres-Saavedra P, Caudell JJ, Waldron JN, et al
    Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).
    J Clin Oncol. 2021;39:956-965.
    PubMed     Abstract available

    January 2021
  54. GEBRE-MEDHIN M, Brun E, Engstrom P, Haugen Cange H, et al
    ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.
    J Clin Oncol. 2021;39:38-47.
    PubMed     Abstract available

  55. SEIWERT TY, Kiess AP
    Time to Debunk an Urban Myth? The "Abscopal Effect" With Radiation and Anti-PD-1.
    J Clin Oncol. 2021;39:1-3.

  56. WIJNHOVEN BPL, Lagarde SM
    Minimally Invasive Esophagectomy: Time to Reflect on Contemporary Outcomes.
    J Clin Oncol. 2021;39:90-91.

  57. NUYTENS F, Voron T, Piessen G
    Hybrid Minimally Invasive Esophagectomy to the Rescue: A Valid Alternative for Phased Dissemination of TMIE?
    J Clin Oncol. 2021;39:91-92.

    December 2020
  58. GARREL R, Poissonnet G, Moya Plana A, Fakhry N, et al
    Equivalence Randomized Trial to Compare Treatment on the Basis of Sentinel Node Biopsy Versus Neck Node Dissection in Operable T1-T2N0 Oral and Oropharyngeal Cancer.
    J Clin Oncol. 2020;38:4010-4018.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.